Merkel Cell Carcinoma – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Merkel Cell Carcinoma – Pipeline Review, H1 2020’, provides an overview of the Merkel Cell Carcinoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Merkel Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Merkel Cell Carcinoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Merkel Cell Carcinoma

– The report reviews pipeline therapeutics for Merkel Cell Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Merkel Cell Carcinoma therapeutics and enlists all their major and minor projects

– The report assesses Merkel Cell Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Merkel Cell Carcinoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Merkel Cell Carcinoma

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Merkel Cell Carcinoma pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

Amgen Inc

Apcure SAS

Arcus Biosciences Inc

Bavarian Nordic A/S

BeiGene Ltd

bluebird bio Inc

Boston Biomedical Inc

Bristol-Myers Squibb Co

Checkpoint Therapeutics Inc

CStone Pharmaceuticals Co Ltd

CytomX Therapeutics Inc

Dragonfly Therapeutics Inc

Eli Lilly and Co

Exelixis Inc

Exicure Inc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

Genexine Inc

Harbin Gloria Pharmaceuticals Co Ltd

ImmunityBio Inc

Immunomic Therapeutics Inc

Incyte Corp

Kartos Therapeutics Inc

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Morphogenesis Inc

NantKwest Inc

Nektar Therapeutics

NextCure Inc

Novartis AG

Ocellaris Pharma Inc

OncoSec Medical Inc

Oncovir Inc

Ono Pharmaceutical Co Ltd

QBiotics Ltd

Replimune Ltd

RHEACELL GmbH & Co KG

Sotio AS

Spring Bank Pharmaceuticals Inc

Tarveda Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Merkel Cell Carcinoma - Overview

Merkel Cell Carcinoma - Therapeutics Development

Merkel Cell Carcinoma - Therapeutics Assessment

Merkel Cell Carcinoma - Companies Involved in Therapeutics Development

Merkel Cell Carcinoma - Drug Profiles

Merkel Cell Carcinoma - Dormant Projects

Merkel Cell Carcinoma - Discontinued Products

Merkel Cell Carcinoma - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Merkel Cell Carcinoma, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Merkel Cell Carcinoma – Pipeline by 4SC AG, H1 2020

Merkel Cell Carcinoma – Pipeline by Amgen Inc, H1 2020

Merkel Cell Carcinoma – Pipeline by Apcure SAS, H1 2020

Merkel Cell Carcinoma – Pipeline by Arcus Biosciences Inc, H1 2020

Merkel Cell Carcinoma – Pipeline by Bavarian Nordic A/S, H1 2020

Merkel Cell Carcinoma – Pipeline by BeiGene Ltd, H1 2020

Merkel Cell Carcinoma – Pipeline by bluebird bio Inc, H1 2020

Merkel Cell Carcinoma – Pipeline by Boston Biomedical Inc, H1 2020

Merkel Cell Carcinoma – Pipeline by Bristol-Myers Squibb Co, H1 2020

Merkel Cell Carcinoma – Pipeline by Checkpoint Therapeutics Inc, H1 2020

Merkel Cell Carcinoma – Pipeline by CStone Pharmaceuticals Co Ltd, H1 2020

Merkel Cell Carcinoma – Pipeline by CytomX Therapeutics Inc, H1 2020

Merkel Cell Carcinoma – Pipeline by Dragonfly Therapeutics Inc, H1 2020

Merkel Cell Carcinoma – Dormant Projects, H1 2020

Merkel Cell Carcinoma – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Merkel Cell Carcinoma, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports